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Abstract
Background
Neoadjuvant therapy has emerged as an alternative treatment strategy for potentially
resectable pancreatic cancer. In the absence of large randomized controlled trials offering a
direct comparison, this study aims to use Markov decision analysis to compare efficacy of
traditional surgery first (SF) and neoadjuvant treatment (NAT) pathways for potentially
resectable pancreatic cancer.
Methods
An advanced Markov decision analysis model was constructed to compare SF and NAT
pathways for potentially resectable pancreatic cancer. Transition probabilities were calcu-
lated from randomized control and Phase II/III trials after comprehensive literature search.
Utility outcomes were measured in overall and quality-adjusted life months (QALMs) on an
intention-to-treat basis as the primary outcome. Markov cohort analysis of treatment
received was the secondary outcome. Model uncertainties were tested with one and two-
way deterministic and probabilistic Monte Carlo sensitivity analysis.
Results
SF gave 23.72 months (18.51 QALMs) versus 20.22 months (16.26 QALMs). Markov
Cohort Analysis showed that where all treatment modalities were received NAT gave 35.05
months (29.87 QALMs) versus 30.96 months (24.86QALMs) for R0 resection and 34.08
months (29.87 QALMs) versus 25.85 months (20.72 QALMs) for R1 resection. One-way
deterministic sensitivity analysis showed that NAT was superior if the resection rate was
greater than 51.04% or below 75.68% in SF pathway. Two-way sensitivity analysis showed
that pathway superiority depended on obtaining multimodal treatment in either pathway.
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Conclusion
Whilst NAT is a viable alternative to traditional SF approach, superior pathway selection
depends on the individual patient’s likelihood of receiving multimodal treatment in either
pathway.
Introduction
Outcomes for pancreatic cancer remain poor despite advances in surgical technique and adju-
vant treatment [1,2]. Early complete surgical resection is the only potentially curative treat-
ment, with surgery followed by adjuvant therapy becoming the standard of care for resectable
pancreatic cancer [3]. Up to 50% of patients fail to receive adjuvant therapy due to: post-opera-
tive complications, early metastases nullifying the potential benefits of high-risk surgery, and
reduced performance status [4,5]. Neoadjuvant therapy (NAT) has emerged as an alternative
to traditional surgery-first (SF) approach. Postulated benefits include: avoiding futile surgery
by identifying aggressive tumour types, eliminating micrometastesis, multimodal treatment
completion and increased R0 resection rates [6,7].
There is a lack of randomized controlled trials (RCTs) comparing SF and NAT [8]. Despite
promising results from cohort studies and phase II trials, meta-analysis have reported only
marginal benefit of NAT in terms of overall and disease-free survival [7,9–12]. Critics have
therefore highlighted the limitations of drawing optimistic conclusions from small studies that
are underpowered [6,7]. Two previous Markov decision-analysis found marginal benefit with
NAT for resectable only cases [9,13]. Only one previous Markov decision analysis compared
efficacy of both pathways for potentially resectable disease and found no conclusively superior
pathway [14].
The aim of this study is to synthesize best current evidence within a Markov decision-analy-
sis model comparing SF and NAT pathways for the management of potentially resectable pan-
creatic cancer on an intention-to-treat basis. This study aims to improve on previous
iterations by performing Markov cohort analysis assessing impact of treatment received on
survival outcomes.
Materials and methods
Markov model
TreeAge Pro 2017 (TreeAge Software Ins., Williamstown, MA) was used to construct a Mar-
kov cohort decision analysis model in an advanced decision-tree format comparing base case,
surgery first followed by adjuvant therapy (which included chemotherapy, chemoradiother-
apy, or both), to NAT (which included chemotherapy and/or chemoradiotherapy) followed by
re-staging and, if possible, surgical resection (Fig 1). Upon completion of treatment, cohorts
entered the Markov health-state transition model with possible survival states including: alive
without disease, alive with disease and dead. Each Markov cycles equated to 1 month with
maximum follow-up of 60-cycles or until death.
Outcome measures
Cumulative payoffs were calculated in life months and quality-adjusted-life-months (QALMs),
which scaled survival from 0 (equivalent to death) to 1 [9,13] based on indicies taken from
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published literature [15,16] andWorld Health Organization and European Quality of Life Sur-
vey [17–19].
Data sources and transition probabilities
Source data was identified through comprehensive literature search of MEDLINE, Embase,
PubMed and Cochrane database and Cochrane database of Clinical Trials following the
PRISMA checklist [20] (S1 Fig). For each of the searches, the entire database was included
from the year 2000 up to and including 31stOctober 2018, with no further date restrictions or
limits applied. Following screening, reference lists and citations of all included papers were
manually searched to identify any additional articles until no new articles were identified. The
lead reviewer performed search design and data extraction with the second author performing
independent quality assurance. Discrepancies were resolved by inter-reviewer discussion. The
following data was extracted from each study: study details (country, year, design, number,
mean age, sex, co-morbidity profile and presenting disease stage of participants), details of
treatment protocols, treatment outcomes (treatment completion rates, rates of tumour resec-
tion, R0 resection rates, drug toxicity data, post-operative complication rates, overall survival
and disease-free survival) and risk of bias data.
Fig 1. Overview of the structure of the Markov decision-tree.
https://doi.org/10.1371/journal.pone.0212805.g001
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The inclusion criteria was RCTs and prospective phase II and III studies of NAT for treat-
ment of pancreatic cancer, published in English language since 2000, involving chemo/radio-
therapy-naive human subjects over 18 years of age with preoperatively staged pancreatic
cancer as potentially resectable. Included trials had to report: protocol design, number of par-
ticipants per arm, median age and co-morbidities of subjects, pre-treatment staging of pancre-
atic cancer, toxicity profile, results of post neoadjuvant re-staging, resection rates, post-
operative complications defined by Clavien-Dindo system, and survival data. Retrospective
and cohort studies, case series and case reports were excluded as were studies from identical
patient cohorts and trials involving intra-operative radiotherapy and trials including disease
other than pancreatic cancer.
As the majority of trials were single arm, to populate the SF pathway the same databases
were searched for RCTs of surgery and adjuvant therapy, with the same inclusion and data
reporting criteria (S2 Fig). The outcomes of this group could introduce biased because by defi-
nition these patients have survived surgery and not developed early metastatic disease and also
had to have adequate performance status to be randomized to adjuvant therapy even if they
did not receive adjuvant therapy. To overcome this issue cohort studies comparing NAT and
SF, with the otherwise same inclusion criteria and data reporting requirements, were also
included in the SF arm and solely used to offer comparison across outcomes of resection, R0
resection rates and receipt of adjuvant therapy (S3 Fig).
The Cochrane Collaboration’s risk of bias tool [21] and ROBINS-I tool (Risk Of Bias In
Non-randomized Studies—of Interventions) [22] were used to assess the quality and risk of
bias of each included trial (S1 and S2 Tables and S4 Fig). Furthermore the potential impact of
bias and uncertainty on all variables within the model were extensively tested through probabi-
listic and deterministic sensitivity analysis.
Statistical analysis
Markov model transition probabilities were based on weighted pooled estimates of propor-
tions from included studies, calculated using Freeman-Tukey arcsine square root transforma-
tion under random effects model to account for heterogeneity [23]. Survival time was based on
time from diagnosis. Gillen et al. approach to calculating weighted median survival time was
used as evidence has shown that weighted averaging of medians cannot achieve unbiased
pooled estimates of survival time [24,25]. This approach is based on averaging parameter esti-
mates of a presumed density function of survival. The pooled distribution parameter is used to
recalculate the estimate of the median from the pooled distribution parameter [24]. In this
case the pooled distribution parameter is the exponential distribution which implies a time
constant hazard rate corresponding to the sole distribution parameter ĕ. From this the
weighted estimate of median survival (mp) is derived from the formula [24]:
mp ¼
Xk
i¼1
wi
mi
� �
  1
wheremi is median survival within the study population i (with i being 1 to k where k is the
number of included studies) [24]. wi is the study specific weight function derived from number
of study participants divided by total number of evaluable patients [24].
Sensitivity analysis
Model uncertainties for all included components were tested with one and two-way determin-
istic sensitivity analysis with baseline transition probabilities for each variable altered between
highest and lowest reported values. Probabilistic Monte Carlo sensitivity analysis was set to
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10000 cycles with model probabilities sampled from the data distribution of each variable.
Data for each variable was fitted against 55 possible distributions with best fit determined by
the Anderson Darling statistic.
Results
50 phase II/III studies met the inclusion criteria and were included in the NAT arm of the
model, 4 of which were randomized. 9 of these studies offered comparison with upfront sur-
gery. For the SF pathway 15 studies were RCTs, 10 of which offered comparison between adju-
vant regimes, 5 of which offered comparison between adjuvant therapy and surgery only. 16
cohort studies were also included in the SF pathway to offer comparison across outcomes of
resection rates, R0 resection, and rates of receiving adjuvant therapy (Table 1). Probability esti-
mates and ranges and quality of life utilities are displayed in Table 2.
Results of Markov decision-analysis
Intention-to-treat analysis of the treatment pathways, based on baseline transition probabili-
ties, showed that SF pathway gave 23.72 months (18.51 QALMs) compared to 20.22 months
(16.26 QALMs) for NAT pathway. The results of Markov cohort analysis are outlined in
Table 3 and demonstrated superiority of the NAT pathway for patients who received all treat-
ment modalities.
Deterministic sensitivity analysis
Deterministic sensitivity analysis tested the sensitivity of the results of the model to variations
in parameters of specific model variables by altering the parameters between highest and low-
est reported values. One-way deterministic sensitivity analysis determined the effect on the
overall results of the model by varying the parameter of each variable individually. Two-way
deterministic sensitivity analysis determined the effect on the model of altering the parameters
of two variables simultaneous.
One-way deterministic sensitivity analysis showed that NAT was the superior treatment
pathway if the probability of achieving resection in the NAT pathway was greater than 51.04%
or the probability of achieving resection in the SF pathway was less than 75.68% (Fig 2).
Two-way deterministic sensitivity analysis demonstrated that treatment superiority
depended on receiving multimodal treatment (resection in NAT pathways and adjuvant ther-
apy in SF pathway). Fig 3A shows the thresholds at which competing pathways offer superior
outcomes with Fig 3B providing corresponding probability thresholds and predicted resulting
quality-adjusted survival time.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis tested the level of confidence in the model output in relation
to uncertainty in model input by determining the distribution of the input data for each vari-
able from the median, standard deviation and variance of the input data. The input data was
then fitted against 55 possible data distributions with the best fit determined by the Anderson
Darling statistic (Table 2). All possible parameter values for each variable within the model
were therefore tested by drawing probabilities from the data distribution when probabilistic
Monte Carlo sensitivity analysis was set to simulate 10000 patients cycling through the model.
The results of probabilistic Monte Carlo sensitivity analysis showed that SF gave a mean
survival time of 19.72 months (range 5.57–22.95) compared to 17.16 months (range 16.50–
17.38) for NAT with standard deviation 2.68 and 0.19, and variance 7.17 and 0.04 in SF and
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Table 1. Summary of included trials.
Reference Type of Study Treatment Regime N = Disease Free Survival in months Overall Survival in months
Al-Sukhun et al. [26] Prospective Phase II Trial CRT + surgery 20 13.4
Cardenes et al.[27] Prospective Phase II Trial CRT + surgery 28 10.3
Casadei et al. [28] Prospective Phase II Trial CRT + surgery 18 28.3
Cetin et al. [29] Prospective Phase II Trial CRT + surgery 11
Chakraborty et al. [30] Prospective Phase II Trial CRT + surgery 13 2.4 9.1
Crane et al. [31] Prospective Phase II Trial CRT + surgery 69 19.2
Epelbaum et al. [32] Prospective Phase II Trial CRT + surgery 20 8
Esnaola et al. [33] Prospective Phase II Trial CRT + surgery 37 10.4 11.8
Evans et al. [34] Prospective Phase II Trial CRT + surgery 86 15.4 22.7
Fiore et al. [35] Prospective Phase II Trial CRT + surgery 34 20 19.2
Golcher et al [36] Prospective Phase II Trial CRT + surgery 121
Golcher et al. [37] Prospective Phase II Trial CRT + surgery 33 8.4 17.4
Heinrich et al. [38] Prospective Phase II Trial CT + surgery 28 9.2 26.5
Herman et al. [39] Prospective Phase II Trial CRT + surgery 49 7.8 13.9
Hong et al. [40] Prospective Phase II Trial CRT + surgery 50 10.4 17.3
Jang et al. [41] Prospective Phase II Trial CRT + surgery 27 21
Jensen et al. [42] Prospective Phase II Trial CRT + surgery 23 11.5
Joensuu et al. [43] Prospective Phase II Trial CRT + surgery 33 18 25
Kim et al. [44] Prospective Phase II Trial CRT + surgery 68 18.2
Landry et al. [45] Prospective Phase II Trial CRT + surgery 21 14.2 19.4
Laurent et al. [46] Prospective Phase II Trial CRT + surgery 22 8 17
Le Scodan et al. [47] Prospective Phase II Trial CRT + surgery 41 9.4
Lee et al. [48] Prospective Phase II Trial CT + surgery 43 10 16.6
Leone et al. [49] Prospective Phase II Trial CRT + surgery 39 10.2 16.7
Lin et al. [50] Prospective Phase II Trial CRT + surgery 42 10.3
Lind et al. [51] Prospective Phase II Trial CRT + surgery 17 19
Magnin et al. [52] Prospective Phase II Trial CRT + surgery 32 16
Magnino et al. [53] Prospective Phase II Trial CRT + surgery 23 14
Marti et al. [54] Prospective Phase II Trial CRT + surgery 26 7 13
Mattiucci et al. [55] Prospective Phase II Trial CRT + surgery 40 15.5
Massucco et al. [56] Prospective Phase II Trial CRT + surgery 28 10 15.4
Maximous et al. [57] Prospective Phase II Trial CRT + surgery 25 12
Mornex et al. [58] Prospective Phase II Trial CRT + surgery 41 9.4
Motoi et al. [59] Prospective Phase II Trial CT+ surgery 35 19.7
Moutardier et al. [60] Prospective Phase II Trial CRT + surgery 19 20
O’Reilly et al.[61] Prospective Phase II Trial CT + surgery 38 27.2
Palmer et al. [62] Prospective Phase II Trial CT + surgery 50 13.6
Pipas et al. [63] Prospective Phase II Trial CRT + surgery 37 17.3
Pister et al. [64] Prospective Phase II Trial CRT + surgery 37 12
Sahora et al.[65] Prospective Phase II Trial CT + surgery 25 16
Satoi et al.[66] Prospective Phase II Trial CRT + surgery 35 24.5
Sherman et al. [67] Prospective Phase II Trial CRT + surgery v CT + surgery 45 34 29/42
Small et al. [68] Prospective Phase II Trial CRT + surgery 29 9.9 11.8
Talamonti et al. [69] Prospective Phase II Trial CRT + surgery 20
Tinchon et al. [70] Prospective Phase II Trial CT + surgery 12
Turrini et al. [71] Prospective Phase II Trial CRT + surgery 34 15.5
Van Buren et al. [72] Prospective Phase II Trial CRT + surgery 59 6.6 16.8
(Continued)
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Table 1. (Continued)
Reference Type of Study Treatment Regime N = Disease Free Survival in months Overall Survival in months
Varadhachary et al. [73] Prospective Phase II Trial CRT + surgery 90 13.2 17.4
Vento et al. [74] Prospective Phase II Trial CRT + surgery 22 30.2
Wilkowski et al. [75] Prospective Phase II Trial CRT + surgery 93 5.6 9.3
Regine et al.[76] RCT Surgery + CRT 230 17.1
Neoptolemos et al. [77] RCT Surgery +CT 551 14.1 23
VanLaethem et al.[78] RCT Surgery +CRT 45 11.8 24.3
Schmidt et al.[79] RCT Surgery +CRT 53 15.2 26.5
Reni et al.[80] RCT Surgery +CRT 51 11.7 26.2
Yoshitomi et al.[81] RCT Surgery +CT 49 12 29.8
Shimoda et al.[82] RCT Surgery +CT 29 14.6 21.5
Uesaka et al.[83] RCT Surgery +CT 187 22.9 46.5
Neoptolemos et al.[84] RCT Surgery +CRT 145 10.7 15.9
Ueno et al.[85] RCT Surgery +CT 58 11.4 22.3
Oettle et al.[86] RCT Surgery +CT 179 13.4 22.8
Kosuge et al.[87] RCT Surgery +CT 45 8.6 12.5
Smeenk et al. [88] RCT Surgery +CRT 110 18 21.6
Morak et al.[89] RCT Surgery +CR 59 12 19
Neoptolemo et al.[90] RCT Surgery + CT 366 25.5
Regine et al.[76] RCT Surgery +CRT 221 20.5
Neoptolemos et al.[77] RCT Surgery +CT 537 14.3 23.6
VanLaethem et al.[78] RCT Surgery +CT 45 10.9 24.4
Schmidt et al.[79] RCT Surgery +CT 57 11.5 28.5
Reni et al.[80] RCT Surgery + CT 49 15.2 31.6
Yoshitomi et al.[81] RCT Surgery + CT 50 2.3 21.2
Shimoda et al.[82] RCT Surgery +CT 28 10.5 18
Uesaka et al.[83] RCT Surgery + CT 190 11.3 25.5
Neoptolemos et al.[84] RCT Surgery +CT 147 15.3 20.1
Ueno et al. [85] RCT Surgery Only 60 5 18.4
Oettle et al.[86] RCT Surgery Only 175 6.7 20.2
Kosuge et al.[87] RCT Surgery Only 44 10.2 15.8
Smeenk et al.[88] RCT Surgery Only 108 14.4 19.2
Morak et al.[89] RCT Surgery Only 61 7 18
Neoptolemo et al.[90] RCT Surgery + CT 364 28
Al-Sukhun et al.[26] Prospective Phase II Trial Surgery + adjuvant therapy 21 18.1
Casadei et al.[28] Prospective Phase II Trial Surgery + adjuvant therapy 20 27.5
Golcher et al. [36] Prospective Phase II Trial Surgery + adjuvant therapy 58 21
Golcher et al.[37] Prospective Phase II Trial Surgery + adjuvant therapy 33 8.7 14.4
Lind et al.[51] Prospective Phase II Trial Surgery + adjuvant therapy 35 11
Massucco et al.[56] Prospective Phase II Trial Surgery + adjuvant therapy 44 8 14
Satoi et al.[66] Prospective Phase II Trial Surgery + adjuvant therapy 41 18.5
Vento et al.[74] Prospective Phase II Trial Surgery + adjuvant therapy 25 35.9
Jang et al.[41] Prospective Phase II Trial Surgery + adjuvant therapy 23 12
DeGus et al.[91] Retrospective Cohort Surgery + adjuvant therapy 6840 24.2
Mellon et al.[92] Retrospective Cohort Surgery + adjuvant therapy 241 22.1
Nurmi et al.[93] Retrospective Cohort Surgery + adjuvant therapy 150 13 26
Shubert et al.[94] Retrospective Cohort Surgery + adjuvant therapy 216 13
Artinya et al.[95] Retrospective Cohort Surgery + adjuvant therapy 419 19
(Continued)
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NAT pathways respectively. When minimum significant difference was set at 3.65 months or
greater, the model reported indifference in superior pathway selection frequency.
Discussion
The role of NAT in treatment of pancreatic cancer is an ongoing area of debate [107]. Markov
decision analysis is a powerful tool offering analysis of complex medical decisions therefore
this study provides important interim analysis and contributes to only three existing studies
that utilize evidence-based Markov decision-analysis to compare NAT and SF pathways
[9,13,14]. Our analysis showed that SF pathway gave an additional 3.5 months (2.25 QALMs)
but neither pathway was conclusively superior. Markov cohort analysis of outcomes where
multimodal treatment was received in both pathways (resection in NAT and adjuvant therapy
in SF) demonstrated superior outcomes with NAT pathway. One-way sensitivity analysis
showed that NAT was superior on in intention-to-treat basis if the probability of resection in
the NAT pathway was above 51.04%. Base-case probability of resection in NAT pathway was
41%. This could represent NAT pathway allowing time to filter out more aggressive tumours,
hence avoiding futile, expensive and high-risk surgery [6,7]. Conversely critics of NAT would
argue that this indicates loosing the window of resectability [6,7]. Critics of NAT have also
raised concerns that it could increase post-operative complications, a claim not substantiated
in our analysis, which is also corroborated by previous studies [9,14].
Three Markov Decision-Analysis studies comparing NAT and SF pathways for pancreatic
cancer exist [9,13,14]. One of these studies most closely resembled this study by focusing on
potentially resectable pancreatic cancer, therefore including borderline and locally advanced
cases in the NAT pathway to capture the effect of conversion to resectability on overall path-
way analysis [9]. As with our findings it did not demonstrate on overall conclusively superior
pathway on an intention-to-treat basis (NAT 18.6 months versus 17.1 months) [14]. Two
other Markov decision analysis studies have reported superiority of NAT pathway but they
focus on resectable only cases and based their model on literature from a single search engine
[13,14]. One study, based on phase I/II trials, reported 22 months for NAT versus 20 months
for SF [9]. De Gus et al. demonstrated larger survival gain with NAT (32.2 versus 26.7 months)
Table 1. (Continued)
Reference Type of Study Treatment Regime N = Disease Free Survival in months Overall Survival in months
Ielpo et al.[96] Prospective Cohort Surgery + adjuvant therapy 36 22.1
Roland et al.[97] Prospective Cohort Surgery + adjuvant therapy 85
DeGus et al. [98] Retrospective Cohort Surgery + adjuvant therapy 11316 Resectable: 24.5
Borderline: 20.0
Locally advanced: 15.5
Mokdad et al.[99] Retrospective Cohort Surgery + adjuvant therapy 6015 21
Chen et al.[100] Retrospective Cohort Surgery + adjuvant therapy 98 17
Tzeng et al.[101] Prospective Cohort Surgery + adjuvant therapy 52 25.3
Fujii et al.[102] Prospective Cohort Surgery + adjuvant therapy 71 13.1
Fujii et al.[103] Prospective Cohort Surgery + adjuvant therapy 416 Resectable: 23.5
Borderline: 20.1
Papalezova et al.[104] Retrospective Cohort Surgery + adjuvant therapy 92 13
Hirono et al.[105] Prospective Cohort Surgery + adjuvant therapy 124 13.7
Murakami et al.[106] Retrospective Cohort Surgery + adjuvant therapy 25 11.6
CRT = chemoradiotherapy CT = chemotherapy
https://doi.org/10.1371/journal.pone.0212805.t001
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but their analysis mostly included retrospective studies [13]. Preliminary results from the PRE-
OPANC-1 trial, a multicenter phase III RCT comparing NAT and SF for borderline resectable
PC, have reported improved survival with NAT on an intention-to-treat basis (17.1 months
Table 2. Summary of transition probabilities, parameters of data distribution and payoff utilities for quality adjusted life months (QALMs).
Variable Baseline Transition
Probability (95% CI)
Range Standard
Deviation
Variance Data Distribution: parameters
(Anderson Darling Statistic)
Study Reference
Grade 3+ toxicity with NAT 0.35 (0.28–0.43) 0–1.0 0.03799 0.00144 Generalized Extreme Value:
k = 0.45856 σ = 0.01111 μ = 0.00904
(0.55904)
[26–35,37–44,46–55,57–64,67–72,75]
Resection in NAT pathway 0.41 (0.33–0.49) 0–0.86 0.00848 7.1972E-
5
Generalized Extreme Value:
k = 0.15727 σ = 0.00545 μ = 0.00618
(0.36129)
[26,27,29–37,41–52,54–61,63–66,68–
69,71,73–75]
Exploratory Laparoscopy/
Laparotomy
0.1 (0.07–0.13) 0–0.36 0.00349 1.2182E-
5
Generalized Pareto: k = 0.06879 σ =
0.00306
μ = -5.1223E-4 (1.3525)
[26–29,32–38,40–45,47–49,51,52,54,56–
69,71–75]
R0 resection NAT pathway 0.29 (0.21–0.36) 0–0.74 0.0068 4.6303E-
5
Johnson SB: č = 1.7195 Ď = 1.0417 ĕ =
0.04849
ξ = -0.00113 (0.35896)
[27–33,35–39,41,43–46,48–51,53–
56,59,61,63,65,66,71,74,75]
Grade 3–4 post-operative
complication NAT pathway
0.35 (0.19–0.53) 0.11–
0.64
0.02702 7.3021E-
4
Generalized Extreme Value: k =
-0.45505 σ = 0.03128 μ = 0.04101
(0.1996)
[28,36,37,41,56,74]
Grade 5 post-operative
complication NAT pathway
0.02 (0.01–0.03) 0–0.36 0.00097 9.4387E-
7
Pareto 2: ċ = 0.34207 Č = 1.3899E-13
(-13.983)
[28,31,34,36–38,40,44,47,48,51,54,56–
61,64,65,67–70,72–74]
Resection SF pathway 0.94 (0.90–0.96) 0.70–
1.0
0.1219 0.01486 Burr:
k = 0.0595 ċ = 10.327
Č = 0.00112
(0.12818)
[26,28,36,37,41,51,56,66,74,91–97,99–106]
R0 resection SF pathway 0.56 (0.51–0.62) 0.16–
0.86
0.09869 0.00974 Pearson 5:
ċ = 0.61636
Č = 7.0460E-4
(0.18259)
[26,28,36,37,41,51,66,74,91–94,96,97,99,101–
106]
Grade 3–4 post-operative
complication SF pathway
0.22 (0.13–0.33) 0.04–
0.54
0.01297 0.0002 Log-Pearson 3:
ċ = 66.845
Č = -0.09425
č = 2.0838
(0.29235)
[28,36,37,41,51,56,74,96,97,101,102]
Grade 5 post-operative
complication SF pathway
0.07(0.02–0.13) 0–0.36 0.00948 8.9795E-
5
Cauchy:
σ = 0.00373
μ = 0.00639
(0.38658)
[28,36,37,41,51,56,74,96,106]
Receiving adjuvant therapy 0.61(0.57–0.66) 0.26–
0.94
0.10088 0.01018 Burr:
k = 0.26048
ċ = 2.145
Č = 9.2071E-4
(0.18949)
[41, 77, 79,92,94,96–99,101,102,104–106]
Adjuvant toxicity grade 3+ 0.43(0.25–0.62) 0.09–
0.98
0.02753 0.00076 Log-Pearson 3:
ċ = 1916.0
Č = -0.02672
č = 47.081
(0.34508)
[76,77,79,81,85,86,88,90]
Survival State Utility for QALM
Living with stable pancreatic
cancer
0.81
Undergoing chemo/radiotherapy 0.81
Experiencing chemo/radiotherapy
complications
0.53
Recovering from pancreatic
surgery
0.59
Experiencing surgical
complications
0.48
Living with unresectable disease
and pre-operative quality-of-life
0.65
https://doi.org/10.1371/journal.pone.0212805.t002
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versus 13.5 months) [108]. Although PREOPANC-1 is a very different study to the one pre-
sented here in terms of design and statistical methodology, the results do echo our findings in
reporting that higher reported resection rates in the SF pathway do not equate with superior
overall survival time for patients treated in a SF pathway [108]. Furthermore the subgroup
analysis of resected cases in the PREOPANC-1 trial reported superior survival time with NAT
(29.9months versus 16.6months), which further corroborates the results our Markov cohort
analysis [108].
Strengths and limitations
Improving upon previous iterations, this study, based on a comprehensive search of multiple
search engines, went beyond intention-to-treat base-case analysis to performMarkov cohort
analysis of treatment received, which provided important results favoring NAT. These findings
corroborate those of prospective and retrospective experiences of NAT, which have demon-
strated favorable survival outcomes ranging from 26 to 45 months [13] and findings reported
by Abbott et al. who, although performing Markov analysis for cost-effectiveness, reported
similar outcomes [109].
Considering at base-case 39% in SF pathway did not received adjuvant therapy and 59% in
NAT pathway did not undergo resection, this adds an important dimension to the ongoing
debate. Two-way sensitivity analysis demonstrated that the superior treatment pathway
depended on an individual’s probability of receiving multimodal treatment in either pathway.
This highlights the need to work towards personalized predictive medicine to assist in the
selection of the most appropriate treatment pathway at individual patient level.
Like existing Markov decision analysis based on data from published studies, this study also
shares the limitations of the existing body of evidence: heterogeneity, lack of randomization,
potential bias, small and underpowered studies [6,7]. Furthermore definitions of radiological
and surgical resectability, R0 resection and staging protocol can vary across trials further com-
pounding the issue of heterogeneity of synthesized data [8]. Such heterogeneity could account
for why, at base-case analysis, the probability of R0 resection in the NAT pathway was smaller
than anticipated particularly when considering that the PREOPANC-1 trial has reported
higher rates of R0 resection (65%) in the NAT arm of their trial [8,108]. Although the uncer-
tainty of this variable was extensively tested through sensitivity analysis and found not to affect
the overall model outcomes, this highlights the potential impact of heterogeneity of data on
model output. To address the issue of heterogeneity, this study based transition probabilities
on weighted pooled proportion estimates calculated using Freeman-Tukey arcsine square root
transformation under random effects model [23]. Furthermore probabilistic Monte Carlo
Table 3. Results fromMarkov cohort analysis.
NAT Pathway SF Pathway
R0 Resection 35.05 months (29.87 QALMs;
POC = 29.76 QALMs)
Received Adjuvant Therapy: 30.96 months (24.86 QALMs; POC = 24.75 QALMs; AT = 21.82
QALMs; POC and AT = 21.71 QALMs) No Adjuvant Therapy: 24.03 months (20.12 QALMs;
POC = 20.01QALMs)
R1 Resection 34.08 months (29.87 QALMs;
POC = 29.76 QALMs)
Received Adjuvant Therapy: 25.85 months (20.72 QALMs; POC = 20.61 QALMs; AT = 18.20
QALMs; POC and AT = 18.09 QALMs) No Adjuvant Therapy: 21.26 months (17.56 QALMs;
POC = 17.45 QALMs)
Exploratory Laparoscopy or
Laparotomy
10.86 months (7.22 QALMs) 10.48 months (6.97 QALMs)
No Surgery 10.86 months (7.06 QALMs)
POC = post-operative complication grade 3 or 4; AT = adjuvant therapy resulting in grade 3 or 4 toxicity
https://doi.org/10.1371/journal.pone.0212805.t003
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Fig 2. One-way deterministic sensitivity analysis. This figure shows the effect of altering the baseline probability of
resection first in the NAT pathway then in the SF pathway on overall model outcome.
https://doi.org/10.1371/journal.pone.0212805.g002
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sensitivity analysis sampled model probabilities from the entire range of the data distribution
and provided assessment of the extent of variance and standard deviation within the model.
Fig 3. Two-way sensitivity analysis. Y-axis shows probability of receiving adjuvant therapy in SF pathway and x-axis
shows probability of receiving resection in NAT pathway. The red area represents where patients, given competing
probability of receiving multimodal treatment in competing pathways, would benefit from SF approach. The blue area
represents where NAT would be the superior treatment option in terms of quality-adjusted survival. The
corresponding predicted survival time in QALMs are detailed below. X and Y-axis provide altering probabilities of
multimodal treatment in each pathway with corresponding survival time given in QALMs.
https://doi.org/10.1371/journal.pone.0212805.g003
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Unlike previous Markov decision-analysis, weighted survival times were based on the Gillen
et al. formulae as evidence has shown that unbiased pooled estimates of median survival times
cannot be achieved by weighted averaging of medians [24,25]. Quality adjusted survival time is
limited by the lack of studies measuring quality-of-life across the treatment trajectory for pan-
creatic cancer. This study utilized best available data that was shared with existing decision-
analysis studies, which enhanced comparability. Our model did not assume return to full
health after an intervention or event but accounted for the impact of therapy, surgery, compli-
cations and disease reoccurrence when calculating quality-adjusted survival. For both survival
and quality-adjusted survival, uncertainty was rigorously tested across every variable in the
model through probabilistic and deterministic sensitivity analysis.
Conclusion
In the absence of large multicenter RCTs, this study utilizes best currently available evidence
in a Markov decision analysis model to provide an important interim source of information
[13,14] to inform the ongoing debate regarding best treatment for potentially resectable pan-
creatic cancer. On an intention-to-treat basis conclusive superiority of either pathway could
not be concluded. However, Markov cohort analysis demonstrated superiority of NAT path-
way if multimodal treatment was received. This highlights three important future directions
for research: 1) cost-effectiveness analysis of NAT versus SF pathways 2) assessment of treat-
ment pathways of resectable only cases hence offering a true like-for-like comparison and 3)
developing methods of personalized predictive statistical modeling to provide individualized
predictions of outcomes across competing treatment pathways to support shared clinical deci-
sion-making.
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